Research programme: hyperphosphataemia therapy - Ilypsa

Drug Profile

Research programme: hyperphosphataemia therapy - Ilypsa

Latest Information Update: 08 Sep 2008

Price : $50

At a glance

  • Originator Ilypsa
  • Class Polymers
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hyperphosphataemia

Most Recent Events

  • 08 Sep 2008 Discontinued - Preclinical for Hyperphosphataemia in USA (unspecified route)
  • 19 Jul 2007 Ilypsa has been acquired by Amgen
  • 21 Jul 2005 Preclinical trials in Hyperphosphataemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top